Sudeep Pharma Limited IPO
Sudeep Pharma is a technology-driven manufacturer of excipients, mineral-based ingredients, and specialty nutritional solutions catering to the global pharmaceutical, food, and nutrition industries. Founded in 1989, the Company has evolved from producing basic excipients to offering a diversified portfolio of 100+ products, with a strong focus on innovation, quality, and global regulatory compliance.
Sudeep Pharma is one of the largest global producers of food-grade iron phosphate, widely used in infant and clinical nutrition, and a leading exporter of mineral ingredients from India. The Company has a total annual manufacturing capacity of 72,246 MT, and is among a select group of global players holding CEP and EU written confirmation approvals for calcium carbonate as an API—underscoring its high-barrier, compliance-driven business model.
Global Presence
Sudeep Pharma has established a strong international footprint, exporting to around 100 countries across the United States, South America, Europe, the Middle East, Africa, and Asia-Pacific. To support global demand, the Company operates dedicated regional sales offices in the US, Europe, UK, and Latin America, supported by stocking arrangements to enhance delivery speed and customer service.
Product Segments
1. Pharmaceutical, Food & Nutrition Ingredients
The Company produces refined mineral-based ingredients such as calcium, zinc, iron, magnesium, copper, sodium, and potassium, used as excipients, APIs (e.g., calcium carbonate), and nutritional fortifiers. These products support diverse applications including pharmaceuticals, dietary supplements, dairy, beverages, bakery, and infant nutrition.
2. Specialty Ingredients (via SNPL)
Through its subsidiary SNPL, Sudeep Pharma manufactures advanced, technology-driven specialty ingredients such as micronutrient premixes, encapsulated ingredients, liposomal formats, granulated minerals, triturated blends, and spray-dried systems. These solutions are designed to enhance bioavailability, nutrient stability, functionality, and manufacturability across food, nutrition, and FMCG industries.
Research & Development Capability
Sudeep Pharma’s R&D strength is a key differentiator. With two R&D facilities and a team of 41 specialists, the Company focuses on particle engineering, nutrient bioavailability, shelf-life enhancement, solvent-free processes, and formulation challenges. The R&D infrastructure, including spray dryers, fluidized bed coaters, tablet compression units, and advanced blending systems, enables continuous product innovation.
Customer Base
Sudeep Pharma serves over 1,100 global customers, including marquee names such as Pfizer, Intas, Mankind Pharma, Merck Group, Alembic, Aurobindo, Cadila, Micro Labs, IMCD Asia, and Danone. The Company enjoys strong customer loyalty, with 78–83% of revenue coming from repeat business in recent fiscals, and long-term relationships averaging 7+ years among its top clients.
Objects of the Sudeep Pharma Limited IPO:
Sudeep Pharma Limited IPO Details:
| Open Date: | Nov 21 2025 |
| Close Date: | Nov 25 2025 |
| Total Shares: | 1,50,92,750 |
| Face Value: | ₹ 1 Per Equity Share |
| Issue Type: | Book Building |
| Issue Size: | 895 Cr. |
| Lot Size: | 25 Shares |
| Issue Price: | ₹ 563 - 593 Per Equity Share |
| Listing At: | NSE,BSE |
| Listing Date: | Nov 28 2025 |
Promoters And Management:
Financials of Sudeep Pharma Limited IPO:
| Particulars | 3M FY2025-26 | FY 2024-25 | FY 2023-2024 | FY 2022-2023 |
| Revenue from Operations (Cr) | 125 | 502 | 459 | 429 |
| EBITDA (Cr) | 49 | 199 | 188 | 99 |
| EBITDA Margins | 38.88% | 39.70% | 40.88% | 23.01% |
| PAT (Cr) | 30.8 | 138.6 | 133.1 | 62.3 |
| PAT Margins | 24.66% | 27.63% | 29.00% | 14.54% |
| ROCE | 5.50% | 29.82% | 41.17% | 29.40% |
| Debt to Equity Ratio(In Times) | 0.14 | 0.20 | 0.17 | 0.32 |
| Operating Cash Flows (Cr) | -5 | 48.7 | 65.6 | 48.3 |
Comparison With Peers:
According to RHP their is no listed peers existed in the same company.
Lead Manager of Sudeep Pharma Limited IPO:
Registrar of Sudeep Pharma Limited IPO:
Discussion on Sudeep Pharma Limited IPO:
Leave a Reply
You must be logged in to post a comment.